Retrospective analysis of patients with hepatocellular carcinoma complicated with human immunodeficiency virus infection after hepatectomy

Table 3 Comparison of clinical parameters between the surgery and non-surgery groups

Clinical parameters	Surgery group	Non-surgery group	P value
Age (years)	60.15 ± 5.90	60.38 ± 7.49	0.223
Gender (male:female)	24:3	23:6	0.472
HBV (positive:negative)	6:21	8:21	0.643
HCV (positive:negative)	2:25	4:25	0.440
CD4+ cell count < 200 (cell/μL)	15 (55.6)	18 (62.1)	0.621
HIV initial diagnosis, n (%)	20 (69.0)	17 (58.6)	0.222
HIV-RNA positive, n (%)	13 (48.1)	20 (69.0)	0.114
Initiation of HART therapy after HIV diagnosis, n (%)	21 (77.8)	12 (41.1)	0.006a
MSM, n (%)	18 (66.7)	14 (48.3)	0.269
Child-Pugh score (A:B)	21:6	14:15	0.023a
BCLC stage (0-B:C-D)	10:17	12:17	0.740
CNLC stage (Ia-IIa:IIb-IIIa)	18:9	14:15	0.165
AFP (ng/mL)	249.00 (3.56-2287.42)	179.01 (1.64-848.74)	0.010a
ALT (U/L)	31.48 ± 22.39	23.66 ± 17.51	0.149
AST (U/L)	37.44 ± 26.24	29.00 ± 20.56	0.184
TBIL	16.31 ± 9.37	14.98 ± 6.82	0.535
DBIL	5.62 ± 4.15	4.29 ± 2.49	0.148
IBIL	10.68 ± 6.53	10.96 ± 4.86	0.859
Prothrombin time (S)	13.55 ± 2.35	13.82 ± 2.11	0.654
Albumin	36.88 ± 5.36	34.37 ± 5.43	0.088
Hemoglobin	135.11 ± 13.37	129.55 ± 14.46	0.142
White blood cell count (/L)	4.84 ± 1.66	5.41 ± 3.95	0.480
Platelet count (/L)	127.11 ± 91.61	168.14 ± 73.22	0.069
Tumor maximum diameter (mm)	46 mm (15-130 mm)	37 mm (9-115 mm)	0.113
Tumor single:multiple	10:17	13:16	0.554
Ascites, n (%)	11 (40.7)	7 (24.1)	0.184
PS score (0-1:2-3)	16:11	19:10	0.629

^aP < 0.05.

HART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; MSM: Men who have sex with men; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin.